Home › Compare › JNSH vs ABBV

JNSH vs ABBV: Dividend Comparison 2026

JNSH yields 102564.10% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNSH wins by $6.222130222302307e+26M in total portfolio value
10 years
JNSH
JNSH
● Live price
102564.10%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.222130222302307e+26M
Annual income
$621,021,919,221,709,700,000,000,000,000,000.00
Full JNSH calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — JNSH vs ABBV

📍 JNSH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJNSHABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JNSH + ABBV cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
JNSH pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JNSH
Annual income on $10K today (after 15% tax)
$8,717,948.72/yr
After 10yr DRIP, annual income (after tax)
$527,868,631,338,453,200,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, JNSH beats the other by $527,868,631,338,453,200,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JNSH + ABBV for your $10,000?

JNSH: 50%ABBV: 50%
100% ABBV50/50100% JNSH
Portfolio after 10yr
$3.111065111151153e+26M
Annual income
$310,510,959,610,854,840,000,000,000,000,000.00/yr
Blended yield
99.81%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

JNSH
No analyst data
Altman Z
4.5
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JNSH buys
0
ABBV buys
0
No recent congressional trades found for JNSH or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJNSHABBV
Forward yield102564.10% ✓3.06%
Annual dividend / share$2.00$6.65 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6% ✓
Portfolio after 10y$6.222130222302307e+26M$102.3K ✓
Annual income after 10y$621,021,919,221,709,700,000,000,000,000,000.00 ✓$24,771.77
Total dividends collected$6.221349690946684e+26M$61.0K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: JNSH vs ABBV ($10,000, DRIP)

YearJNSH PortfolioJNSH Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,267,110$10,256,410.26$11,550$430.00+$10.26M → JNSH
2$9,852,452,625$9,841,466,816.59$13,472$627.96+$9852.44M → JNSH
3$8,836,710,012,281$8,826,167,887,973.18$15,906$926.08+$8836710.00M → JNSH
4$7,407,801,558,405,960$7,398,346,278,692,819.00$19,071$1,382.55+$7407801558.39M → JNSH
5$5,804,209,774,032,727,000$5,796,283,426,365,233,000.00$23,302$2,095.81+$5804209774032.70M → JNSH
6$4,250,642,660,057,558,300,000$4,244,432,155,599,343,500,000.00$29,150$3,237.93+$4250642660057558.50M → JNSH
7$2,909,556,067,391,994,000,000,000$2,905,007,879,745,732,500,000,000.00$37,536$5,121.41+$2909556067391993856.00M → JNSH
8$1,861,498,137,778,888,800,000,000,000$1,858,384,912,786,779,500,000,000,000.00$50,079$8,338.38+$1.861498137778889e+21M → JNSH
9$1,113,180,381,795,297,600,000,000,000,000$1,111,188,578,787,874,300,000,000,000,000.00$69,753$14,065.80+$1.1131803817952976e+24M → JNSH
10$622,213,022,230,230,600,000,000,000,000,000$621,021,919,221,709,700,000,000,000,000,000.00$102,337$24,771.77+$6.222130222302307e+26M → JNSH

JNSH vs ABBV: Complete Analysis 2026

JNSH — Stock

JNS Holdings Corporation, through its subsidiaries, operates as an electrical design build construction services contractor in the United States. The company is based in Wheeling, Illinois.

Full JNSH Calculator →

ABBV — Healthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this JNSH vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JNSH vs SCHDJNSH vs JEPIJNSH vs OJNSH vs KOJNSH vs MAINJNSH vs JNJJNSH vs MRKJNSH vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.